Cardio-oncology imaging tools at the translational interface

J Mol Cell Cardiol. 2022 Jul:168:24-32. doi: 10.1016/j.yjmcc.2022.03.012. Epub 2022 Apr 3.

Abstract

Cardiovascular imaging is an evolving component in the care of cancer patients. With improved survival following prompt cancer treatment, patients are facing increased risks of cardiovascular complications. While currently established imaging modalities are providing useful structural mechanical information, they continue to develop towards increased specificity. New modalities, emerging from basic science and oncology, are being translated, targeting earlier stages of cardiovascular disease. Besides these technical advances, matching an imaging modality with the patients' individual risk level for a specific pathological change is part of a successful imaging strategy. The choice of suitable imaging modalities and time points for specific patients will impact the cardio-oncological risk stratification during surveillance and follow-up monitoring. In addition, future imaging tools are poised to give us important insights into the underlying cardiovascular molecular pathology associated with cancer and oncological therapies. This review aims at giving an overview of the novel imaging technologies that have the potential to change cardio-oncological science and clinical practice in the near future.

Keywords: Cardio-oncology; Cardiotoxicity; Cardiovascular imaging.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Cardiotoxicity / etiology
  • Cardiovascular Diseases* / etiology
  • Heart Diseases* / drug therapy
  • Humans
  • Medical Oncology / methods
  • Neoplasms* / complications

Substances

  • Antineoplastic Agents